GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » Market Cap

Panacea Acquisition II (Panacea Acquisition II) Market Cap : $241.10 Mil (As of May. 22, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Acquisition II Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Panacea Acquisition II's share price for the quarter that ended in Dec. 2022 was $10.05. Panacea Acquisition II's Shares Outstanding (EOP) for the quarter that ended in Dec. 2022 was 23.55 Mil. Therefore, Panacea Acquisition II's market cap for the quarter that ended in Dec. 2022 was $236.63 Mil.

Panacea Acquisition II's quarterly market cap increased from Jun. 2022 ($229.80 Mil) to Sep. 2022 ($230.74 Mil) and increased from Sep. 2022 ($230.74 Mil) to Dec. 2022 ($236.63 Mil).

Panacea Acquisition II's annual market cap increased from . 20 ($0.00 Mil) to Dec. 2021 ($228.39 Mil) and increased from Dec. 2021 ($228.39 Mil) to Dec. 2022 ($236.63 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Panacea Acquisition II's Enterprise Value for Today is $241.03 Mil.


Panacea Acquisition II Market Cap Historical Data

The historical data trend for Panacea Acquisition II's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Acquisition II Market Cap Chart

Panacea Acquisition II Annual Data
Trend Dec21 Dec22
Market Cap
228.39 236.63

Panacea Acquisition II Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Market Cap Get a 7-Day Free Trial 228.39 229.56 229.80 230.74 236.63

Competitive Comparison of Panacea Acquisition II's Market Cap

For the Shell Companies subindustry, Panacea Acquisition II's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Acquisition II's Market Cap Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Panacea Acquisition II's Market Cap distribution charts can be found below:

* The bar in red indicates where Panacea Acquisition II's Market Cap falls into.



Panacea Acquisition II Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Panacea Acquisition II's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )=Share Price (A: Dec. 2022 )*Shares Outstanding (EOP) (A: Dec. 2022 )
=$10.05*23.545
=$236.63

Panacea Acquisition II's Market Cap for the quarter that ended in Dec. 2022 is calculated as

Market Cap (Q: Dec. 2022 )=Share Price (Q: Dec. 2022 )*Shares Outstanding (EOP) (Q: Dec. 2022 )
=$10.05*23.545
=$236.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Acquisition II  (NAS:PANA) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Panacea Acquisition II Market Cap Related Terms

Thank you for viewing the detailed overview of Panacea Acquisition II's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Acquisition II (Panacea Acquisition II) Business Description

Traded in Other Exchanges
N/A
Address
357 Tehama Street, Floor 3, San Francisco, CA, USA, 94103
Website
Panacea Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Executives
Ecor1 Capital Fund Qualified, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Venture Opportunity Fund, Lp director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc director, 10 percent owner 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Panacea Holdings Ii, Llc director, 10 percent owner 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Douglas E. Giordano director C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Praveen P. Tipirneni director C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Sarah Marriott director, officer: Secretary C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Perlen officer: Chief Financial Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Caroline Stout officer: Chief Investment Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Platshon officer: Chief Operating Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103

Panacea Acquisition II (Panacea Acquisition II) Headlines